Altamira Historical Financial Ratios

CYTO Stock

USD 0.43 0.01 2.38%

Altamira Therapeutics is presently reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.23 or Days Sales Outstanding of 7.36 will help investors to properly organize and evaluate Altamira Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.

About Altamira Financial Ratios Analysis

Altamira TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Altamira Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Altamira financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Altamira Therapeutics history.

Altamira Therapeutics Financial Ratios Chart

At this time, Altamira Therapeutics' EV To Sales is very stable compared to the past year. As of the 26th of November 2024, Sales General And Administrative To Revenue is likely to grow to 10.89, while Book Value Per Share is likely to drop 12.50.

Average Payables Inventory Turnover Days Of Inventory On Hand Payables Turnover Interest Coverage Price To Book Ratio

Add Fundamental

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Price To Book Ratio

A ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share.

Most ratios from Altamira Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Altamira Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.At this time, Altamira Therapeutics' EV To Sales is very stable compared to the past year. As of the 26th of November 2024, Sales General And Administrative To Revenue is likely to grow to 10.89, while Book Value Per Share is likely to drop 12.50.

	2010	2022	2023	2024 (projected)
Payables Turnover	0.63	0.3	0.35	0.52
Days Of Inventory On Hand	136.71	2.94	3.39	3.22

Payables Turnover Days Of Inventory On Hand

Altamira Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		-0.15	1.0	-0.52	-0.14	0.47	0.17	0.2	-0.15	1.0	0.46	0.15	0.12	0.48	-0.12	-0.11	0.32	0.12	-0.46	-0.03	0.98	-0.25	-0.02	0.1	0.07	0.17
Ptb Ratio	-0.15		-0.12	0.27	-0.29	-0.1	-0.29	0.2	1.0	-0.14	-0.1	-0.93	0.25	-0.1	-0.25	-0.23	-0.46	0.05	0.32	0.96	-0.06	-0.39	0.96	0.22	0.15	-0.92
Days Sales Outstanding	1.0	-0.12		-0.54	-0.14	0.5	0.11	0.26	-0.12	0.99	0.49	0.12	0.12	0.51	-0.12	-0.11	0.27	0.05	-0.48	0.0	0.99	-0.3	0.01	0.1	0.07	0.14
Book Value Per Share	-0.52	0.27	-0.54		0.27	-0.69	0.06	-0.26	0.27	-0.52	-0.71	-0.26	-0.25	-0.67	0.25	0.23	-0.42	-0.06	0.94	0.05	-0.59	0.36	0.05	-0.22	-0.13	-0.3
Free Cash Flow Yield	-0.14	-0.29	-0.14	0.27		-0.48	-0.13	0.01	-0.29	-0.14	-0.49	0.24	-0.87	-0.48	0.89	0.71	-0.36	-0.07	0.34	-0.41	-0.22	0.49	-0.41	-0.65	-0.88	0.31
Operating Cash Flow Per Share	0.47	-0.1	0.5	-0.69	-0.48		0.09	0.56	-0.1	0.47	1.0	0.17	0.46	1.0	-0.46	-0.42	0.37	0.11	-0.86	0.11	0.51	-0.76	0.11	0.4	0.27	0.04
Average Payables	0.17	-0.29	0.11	0.06	-0.13	0.09		-0.39	-0.29	0.18	0.08	0.45	0.34	0.08	-0.33	-0.45	0.78	0.48	0.02	-0.32	0.09	0.17	-0.32	0.47	-0.02	0.22
Capex To Depreciation	0.2	0.2	0.26	-0.26	0.01	0.56	-0.39		0.2	0.19	0.56	-0.2	-0.11	0.56	0.11	0.12	-0.28	-0.2	-0.38	0.27	0.22	-0.84	0.28	-0.12	-0.1	-0.26
Pb Ratio	-0.15	1.0	-0.12	0.27	-0.29	-0.1	-0.29	0.2		-0.14	-0.1	-0.93	0.25	-0.1	-0.25	-0.23	-0.46	0.05	0.32	0.96	-0.06	-0.39	0.96	0.22	0.15	-0.92
Ev To Sales	1.0	-0.14	0.99	-0.52	-0.14	0.47	0.18	0.19	-0.14		0.47	0.14	0.13	0.48	-0.13	-0.12	0.32	0.13	-0.46	-0.02	0.98	-0.25	-0.02	0.11	0.07	0.16
Free Cash Flow Per Share	0.46	-0.1	0.49	-0.71	-0.49	1.0	0.08	0.56	-0.1	0.47		0.17	0.46	1.0	-0.46	-0.43	0.38	0.11	-0.87	0.11	0.5	-0.76	0.12	0.41	0.27	0.05
Roic	0.15	-0.93	0.12	-0.26	0.24	0.17	0.45	-0.2	-0.93	0.14	0.17		-0.03	0.17	0.04	-0.04	0.56	-0.02	-0.33	-0.89	0.08	0.3	-0.89	0.06	-0.25	0.87
Inventory Turnover	0.12	0.25	0.12	-0.25	-0.87	0.46	0.34	-0.11	0.25	0.13	0.46	-0.03		0.45	-1.0	-0.92	0.47	0.11	-0.31	0.35	0.2	-0.42	0.35	0.88	0.59	-0.21
Net Income Per Share	0.48	-0.1	0.51	-0.67	-0.48	1.0	0.08	0.56	-0.1	0.48	1.0	0.17	0.45		-0.45	-0.41	0.35	0.1	-0.85	0.11	0.51	-0.76	0.11	0.39	0.28	0.05
Days Of Inventory On Hand	-0.12	-0.25	-0.12	0.25	0.89	-0.46	-0.33	0.11	-0.25	-0.13	-0.46	0.04	-1.0	-0.45		0.92	-0.47	-0.11	0.31	-0.35	-0.2	0.42	-0.35	-0.88	-0.62	0.22
Payables Turnover	-0.11	-0.23	-0.11	0.23	0.71	-0.42	-0.45	0.12	-0.23	-0.12	-0.43	-0.04	-0.92	-0.41	0.92		-0.43	-0.1	0.29	-0.32	-0.18	0.36	-0.32	-1.0	-0.36	0.17
Average Inventory	0.32	-0.46	0.27	-0.42	-0.36	0.37	0.78	-0.28	-0.46	0.32	0.38	0.56	0.47	0.35	-0.47	-0.43		0.38	-0.4	-0.42	0.27	0.02	-0.42	0.41	0.26	0.39
Capex To Revenue	0.12	0.05	0.05	-0.06	-0.07	0.11	0.48	-0.2	0.05	0.13	0.11	-0.02	0.11	0.1	-0.11	-0.1	0.38		-0.07	0.06	0.09	-0.01	0.06	0.1	-0.07	-0.05
Cash Per Share	-0.46	0.32	-0.48	0.94	0.34	-0.86	0.02	-0.38	0.32	-0.46	-0.87	-0.33	-0.31	-0.85	0.31	0.29	-0.4	-0.07		0.08	-0.51	0.5	0.08	-0.27	-0.18	-0.32
Pocfratio	-0.03	0.96	0.0	0.05	-0.41	0.11	-0.32	0.27	0.96	-0.02	0.11	-0.89	0.35	0.11	-0.35	-0.32	-0.42	0.06	0.08		0.08	-0.52	1.0	0.31	0.22	-0.87
Interest Coverage	0.98	-0.06	0.99	-0.59	-0.22	0.51	0.09	0.22	-0.06	0.98	0.5	0.08	0.2	0.51	-0.2	-0.18	0.27	0.09	-0.51	0.08		-0.31	0.09	0.17	0.12	0.09
Capex To Operating Cash Flow	-0.25	-0.39	-0.3	0.36	0.49	-0.76	0.17	-0.84	-0.39	-0.25	-0.76	0.3	-0.42	-0.76	0.42	0.36	0.02	-0.01	0.5	-0.52	-0.31		-0.53	-0.34	-0.26	0.44
Pfcf Ratio	-0.02	0.96	0.01	0.05	-0.41	0.11	-0.32	0.28	0.96	-0.02	0.12	-0.89	0.35	0.11	-0.35	-0.32	-0.42	0.06	0.08	1.0	0.09	-0.53		0.31	0.22	-0.87
Days Payables Outstanding	0.1	0.22	0.1	-0.22	-0.65	0.4	0.47	-0.12	0.22	0.11	0.41	0.06	0.88	0.39	-0.88	-1.0	0.41	0.1	-0.27	0.31	0.17	-0.34	0.31		0.28	-0.15
Income Quality	0.07	0.15	0.07	-0.13	-0.88	0.27	-0.02	-0.1	0.15	0.07	0.27	-0.25	0.59	0.28	-0.62	-0.36	0.26	-0.07	-0.18	0.22	0.12	-0.26	0.22	0.28		-0.21
Roe	0.17	-0.92	0.14	-0.3	0.31	0.04	0.22	-0.26	-0.92	0.16	0.05	0.87	-0.21	0.05	0.22	0.17	0.39	-0.05	-0.32	-0.87	0.09	0.44	-0.87	-0.15	-0.21

Click cells to compare fundamentals

Altamira Therapeutics Account Relationship Matchups

Altamira Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	(162.77)	79.98	343.11	13.36	12.02	12.62
Ptb Ratio	1.51	0.83	1.73	(0.49)	0.22	0.23
Book Value Per Share	415.0	1.1K	383.64	(182.6)	13.15	12.5
Free Cash Flow Yield	(1.25)	(0.51)	(0.78)	(2.65)	(8.01)	(7.61)
Operating Cash Flow Per Share	(577.07)	(322.15)	(412.87)	(190.69)	(23.44)	(24.62)
Stock Based Compensation To Revenue	(4.05)	2.11	18.88	1.12	1.01	1.24
Capex To Depreciation	97.93	115.55	43.56	18.02	16.22	24.7
Pb Ratio	1.51	0.83	1.73	(0.49)	0.22	0.23
Ev To Sales	(138.05)	18.45	336.72	34.02	30.62	32.15
Free Cash Flow Per Share	(784.6)	(476.14)	(513.31)	(237.75)	(23.44)	(24.62)
Roic	(1.17)	(0.3)	(1.35)	10.68	(0.92)	(0.87)
Net Income Per Share	(455.96)	(545.41)	(525.13)	(582.58)	(14.81)	(15.55)
Sales General And Administrative To Revenue	(70.25)	14.87	76.64	11.52	10.37	10.89
Research And Ddevelopement To Revenue	(59.38)	16.41	139.93	64.39	57.95	60.85
Capex To Revenue	(53.9)	13.27	52.06	7.01	6.31	6.63
Cash Per Share	95.2	748.84	29.72	0.34	1.26	1.19
Pocfratio	(1.09)	(2.88)	(1.6)	(0.47)	(0.12)	(0.13)
Interest Coverage	(253.57)	(39.09)	(90.14)	(28.66)	(25.79)	(27.08)
Capex To Operating Cash Flow	(0.36)	(0.48)	(0.24)	(0.25)	(0.28)	(0.3)
Pfcf Ratio	(0.8)	(1.95)	(1.29)	(0.38)	(0.12)	(0.13)
Income Quality	1.27	0.59	0.79	0.33	2.98	3.12
Roe	(1.1)	(0.49)	(1.37)	3.19	(1.13)	(1.07)
Ev To Operating Cash Flow	(0.92)	(0.66)	(1.57)	(1.2)	(0.0798)	(0.0838)
Pe Ratio	(1.37)	(1.7)	(1.26)	(0.15)	(0.2)	(0.21)
Return On Tangible Assets	(2.7)	(0.7)	(3.84)	(11.01)	(1.91)	(2.01)
Earnings Yield	(0.73)	(0.59)	(0.79)	(6.5)	(5.06)	(4.81)
Intangibles To Total Assets	0.36	0.73	0.44	0.76	0.62	0.51
Net Debt To E B I T D A	0.36	0.19	2.04	0.0608	(0.36)	0.38
Current Ratio	1.04	3.83	0.77	0.14	1.38	1.31
Tangible Book Value Per Share	(50.15)	509.11	(48.63)	(268.11)	5.22	4.96
Graham Number	2.1K	3.7K	2.1K	1.5K	66.2	62.89
Shareholders Equity Per Share	415.0	1.1K	383.64	(182.6)	13.15	12.5
Debt To Equity	(4.68)	0.39	0.0312	(0.71)	(0.81)	(0.85)
Capex Per Share	207.54	153.99	100.43	47.06	54.12	51.41
Graham Net Net	(34.1K)	(11.4K)	(142.35)	(320.44)	(1.14)	(1.09)

Pair Trading with Altamira Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altamira Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altamira Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Altamira Stock

0.71	ME	23Andme Holding	Pair Corr
0.92	VALN	Valneva SE ADR	Pair Corr
0.75	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

Moving against Altamira Stock

0.66	KZR	Kezar Life Sciences	Pair Corr
0.55	MLYS	Mineralys Therapeutics,	Pair Corr
0.39	MDGL	Madrigal Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Altamira Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altamira Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altamira Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altamira Therapeutics to buy it.

The correlation of Altamira Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altamira Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altamira Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Altamira Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Altamira Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Altamira Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Altamira Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Altamira Therapeutics Stock:

How To Invest In Altamira

Details

Is Altamira Stock a good investment?

Details

What is Altamira Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

1.82

Revenue Per Share

0.917

Quarterly Revenue Growth

(0.64)

Return On Assets

(0.57)

Return On Equity

(3.69)

The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity	Operating Cycle
Cash Conversion Cycle

Altamira Historical Financial Ratios

About Altamira Financial Ratios Analysis

Altamira Therapeutics Financial Ratios Chart

Average Payables

Inventory Turnover

Payables Turnover

Price To Book Ratio

Altamira Therapeutics fundamentals Correlations

Altamira Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Altamira Therapeutics fundamentals Accounts

Pair Trading with Altamira Therapeutics

Moving together with Altamira Stock

Moving against Altamira Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Days Sales Outstanding	+ 1.0	Price To Sales Ratio
Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Free Cash Flow Per Share

Days Payables Outstanding	- 1.0	Payables Turnover
Days Of Inventory On Hand	- 1.0	Inventory Turnover
Roic	- 0.93	Pb Ratio
Roic	- 0.93	Ptb Ratio
Payables Turnover	- 0.92	Inventory Turnover
Roe	- 0.92	Pb Ratio